Autoantibody response against ANXA1 is previously reported in lung cancer and is one of the proteins among the panel of six TAAs (p53, NY-ESO1, Annexin I, CAGE, GBU4–5, and SOX2) that can detect up to 40% of all lung cancers in the disease groups, with a specificity of 90% [22, 23]. The gene discussed is SOX2; the disease is lung carcinoma.